Table II.

Therapeutic efficacy of adoptively transferred Tc1 or Tc2 effector cells at different levels of tumor developmenta

Therapy (i.v.)Days PosttherapyMean No. of Lung Metastases ± SEMb
7-Day-established tumor14-Day-established tumor
Tc173.3 ± 0.3∗∗110.3 ± 4.3
1432.3 ± 14.1∗∗45.3 ± 0.3∗
2139.0 ± 4.0∗38.5 ± 3.5∗
Tc2714.0 ± 1.1∗∗82.0 ± 18.4
1421.7 ± 6.1∗∗68.0 ± 2.9∗
2127.3 ± 4.3∗20.0 ± 3.0∗
None769.0 ± 17.8105.3 ± 7.5
14113.7 ± 13.5>250
21>250>250
  • a Mice (n = 10/group) were injected i.v. with 5 × 105 B16-OVA tumor cells. Tc1 or Tc2 effector cells were adoptively transferred into mice bearing established 7-day (early tumor development) or 14-day (late tumor development) metastases.

  • b Lungs (n = 3/group) were harvested at 7-day intervals after therapy and tumor foci were counted as described in Materials and Methods. p value for treated animals vs untreated animals: ∗, p < 0.001; ∗∗, p < 0.01.